Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yuxintong capsule for cardiopulmonary exercise tolerance in stable coronary artery disease with cardiac insufficiency
ChiCTR2400084917Phase 4Not yet recruiting
- Sponsor
- Xiyuan Hospital
- Start
- Mar 2024
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Yuxintong in coronary arteriosclerosis and chronic heart failure (CHF) (2 arms), sponsored by Xiyuan Hospital. Primary endpoint: Peak oxygen uptake. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
Yuxintong
03
Conditions
coronary arteriosclerosischronic heart failure (CHF)
Beyond the preview
Go deeper on ChiCTR2400084917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084917.